Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
Abstract Lung cancer is the leading cause of cancer mortality. As a heterogeneous disease, it has different subtypes and various treatment modalities. In addition to conventional surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have also been applied in the clinics. However...
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
BMC
2023-03-01
|
| Sarja: | Cancer Nanotechnology |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s12645-023-00174-x |